Buy, Sell or Hold: Prometheus Biosciences (RXDX-Q)

Prometheus Biosciences (RXDX-Q)

NASDAQ:RXDX

199.92

0.00 (0.00%) 1d

BUY

They make drugs to treat inflammatory bowel diseases, a big market. Last Wednesday they announced strong phase 2 trial data for a leading IBD drug. Shares soared 166% on Wednesday. This drug will mae RXDX a major pharma.

Showing 1 to 1 of 1 entries

Prometheus Biosciences(RXDX-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Prometheus Biosciences is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Prometheus Biosciences(RXDX-Q) Frequently Asked Questions

What is Prometheus Biosciences stock symbol?

Prometheus Biosciences is a American stock, trading under the symbol RXDX-Q on the NASDAQ (RXDX). It is usually referred to as NASDAQ:RXDX or RXDX-Q

Is Prometheus Biosciences a buy or a sell?

In the last year, there was no coverage of Prometheus Biosciences published on Stockchase.

Is Prometheus Biosciences a good investment or a top pick?

Prometheus Biosciences was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Prometheus Biosciences.

Why is Prometheus Biosciences stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Prometheus Biosciences worth watching?

In the last year, there was no coverage of Prometheus Biosciences published on Stockchase.

What is Prometheus Biosciences stock price?

On 2023-06-15, Prometheus Biosciences (RXDX-Q) stock closed at a price of $199.92.

Most Recent Experts

Daniel Straus

National Bank Financial

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase Insights

5i Research

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.